Aspire Biopharma Holdings (ASBP) EBT (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has reported EBT for 3 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 35.99% year-over-year to -$1.3 million in Q2 2026; TTM through Jun 2026 was -$15.2 million, a 19.18% increase from a year earlier, with the FY2025 full-year figure at -$24.5 million, down 1770.4% from the prior year.
• EBT was -$1.3 million for Q2 2026 at Aspire Biopharma Holdings, up from -$3.2 million in the prior quarter.
• Over five years, EBT peaked at -$215256.0 in Q3 2024 and troughed at -$15.9 million in Q1 2025.
• A 3-year average of -$4.3 million and a median of -$2.3 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT sank 1119.74% in 2025 and jumped 79.78% in 2026, its largest moves.
• Over 3 years, EBT stood at -$667722.0 in 2024, then tumbled by 1110.51% to -$8.1 million in 2025, then jumped by 84.31% to -$1.3 million in 2026.
• The last three EBT figures came in at -$1.3 million (Q2 2026), -$3.2 million (Q1 2026), and -$8.1 million (Q4 2025), per Business Quant data.